Pharmaceutical companies in Europe are feeling anxious about a potential "exodus" to the US as recent developments cause stocks to tumble. Shares in drugmakers across the EU and India slipped after Donald Trump hinted at new tariffs on drug imports.
On the morning of the announcement, European healthcare stocks dropped by 3.9%, reaching their lowest point since October 2022. Major firms like AstraZeneca, GSK, Roche, and Sanofi saw declines of over 5% each. Even in India, where companies like Teva produce a wide range of medicines, fears grew as the global market reacted to Trump’s threats.
Trump’s recent tariffs, which include a hefty 20% levy on goods from the EU, add pressure to an industry already wary of increasing costs. During a speech, he insisted that the tariffs would encourage drug companies to shift their operations back to the US, although he hasn’t specified when this would happen or the exact amount of the increase.
European drug firms have urged the European Commission president, Ursula von der Leyen, to take “rapid and radical action” against this risk. They fear that without swift measures, research and manufacturing could be directed toward the US instead, leading to significant job losses in Europe.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) recently expressed concerns over a survey indicating that 10% of planned investments—about €16.5 billion—could be at risk due to this uncertainty.
A historical context can help us understand this situation better. In the past, the pharmaceutical industry faced rising pressures and competition, often responding with calls for government support. For instance, during the late 1990s and early 2000s, similar fears over job losses led European firms to seek favorable regulatory environments. This time, however, the stakes seem even higher. According to EFPIA, the U.S. is now perceived as more appealing for investments, with faster approval processes and better rewards for innovation.
Social media reactions also reflect the public’s growing concern. Many users are speaking out about the impact of these tariffs, sharing worries that higher drug costs may lead to reduced access to essential medications. This sentiment echoes broader discussions about healthcare affordability and access, topics that remain hot-button issues.
As the pharmaceutical landscape shifts, the next few months will be crucial. Companies are pressing for policy changes that could help retain investments in Europe, such as enhancing intellectual property protections and fostering a more supportive environment for research and development.
For more detailed information on the current state of the pharmaceutical market and the potential impacts of U.S. tariffs, you can read the latest reports from EFPIA here.
Check out this related article: EU Strikes Back: Countries Unite to Approve Over €20 Billion in Retaliatory Measures Against Trump’s Tariffs
Source link